For instance, both genes NRG1 and CHEK1 have their variations in expression associated with either pre-clinical (CHEK1) or clinical (NRG1) evidence level for drugs against lung small cell carcinoma (CHEK1, prexasertib in combination with olaparib or cisplatin) and lung non-small cell carcinoma (NRG1, patritumab) according to CIViC database. This evidence concerns the gene CHEK1 and small cell lung carcinoma.